Who Owns Novo Nordisk?

Novo Nordisk operates with a sustainability framework focused on environmental responsibility, access to health, and ethical business practices, integrated into its business model through the "Novo Nordisk Way."

Environmental Responsibility: Novo Nordisk has committed to achieving zero environmental impact and has set targets for reducing CO2 emissions, water consumption, and waste across its operations and supply chain. The company has implemented environmental management systems at its manufacturing facilities and has invested in renewable energy and energy efficiency.

Access to Health: Novo Nordisk operates access-to-medicines programs that provide insulin and diabetes care products at affordable prices in low- and middle-income countries. The company's access programs include the Changing Diabetes program, which supports diabetes prevention and care in communities worldwide.

Ethical Business Practices: Novo Nordisk maintains a comprehensive ethics framework based on the Novo Nordisk Way, which includes commitments to transparency, integrity, and responsible business conduct. The company publishes detailed sustainability reports and has been recognized for its ethical practices.

Deforestation-free Supply Chain: Novo Nordisk has committed to ensuring that its supply chain is free from deforestation, particularly in the sourcing of ingredients used in its pharmaceutical products.

Patient Safety and Product Quality: Novo Nordisk maintains rigorous patient safety and product quality standards across its manufacturing operations, with quality management systems that meet regulatory requirements worldwide.

Novo Nordisk has received recognition for its business practices, sustainability initiatives, and contributions to healthcare.

Sustainability Leadership: Novo Nordisk has been recognized as one of the world's most sustainable corporations by multiple organizations and indices, including the Dow Jones Sustainability Index and Corporate Knights.

Innovation in Diabetes Care: Novo Nordisk has been recognized for its pioneering work in diabetes treatment, including the development of insulin products, GLP-1 receptor agonists, and next-generation treatments. The development of semaglutide transformed diabetes and obesity treatment.

Corporate Ethics and Transparency: Novo Nordisk has received recognition for its ethical business practices, transparency, and corporate governance. The company's adherence to the Novo Nordisk Way and comprehensive sustainability reporting have been acknowledged by business ethics organizations.

Market Leadership: Novo Nordisk has been recognized for its market leadership in diabetes care and obesity treatment, with Ozempic and Wegovy becoming among the best-selling pharmaceutical products in the world.

Employer of Choice: Novo Nordisk has been recognized as a top employer in the pharmaceutical industry and in Denmark, with awards for workplace quality, diversity, and employee development.

CagriSema Trial Disappointment (December 2024): Novo Nordisk announced that CagriSema achieved only 22.7% weight loss in its Phase 3 REDEFINE 2 trial, falling short of the 25% target and investor expectations. The stock dropped approximately 17%, wiping out approximately $80 billion in market value. The results were particularly disappointing because they did not demonstrate a clear advantage over Eli Lilly's tirzepatide.

CEO Departure (March 2025): CEO Lars Fruergaard Jorgensen departed Novo Nordisk in March 2025, with board chairman Helge Lund assuming interim leadership. The departure followed investor pressure after the CagriSema disappointment and the competitive threat from Eli Lilly. The CEO departure created leadership uncertainty at a critical competitive moment.

Supply Constraints for Ozempic and Wegovy: Novo Nordisk has faced periodic supply shortages for Ozempic and Wegovy due to demand exceeding manufacturing capacity. The shortages led to rationing of supplies, with some patients unable to access their prescribed medications. Novo Nordisk has invested billions in expanding manufacturing capacity but has struggled to keep pace with surging global demand.

Ozempic Off-Label Use Controversy: The widespread off-label use of Ozempic for weight loss has created controversy, as demand from non-diabetic users has contributed to supply shortages for type 2 diabetes patients. Medical professionals and patient advocacy groups have raised concerns about the ethical implications of using a diabetes medication for cosmetic weight loss.

Safety Concerns: Novo Nordisk has faced scrutiny over potential side effects of semaglutide, including gastrointestinal issues, muscle loss, and rare cases of pancreatitis and thyroid tumors. Regulatory agencies including the FDA and European Medicines Agency (EMA) have monitored the safety profile of GLP-1 receptor agonists and have issued warnings about potential risks.

Competition from Eli Lilly: Novo Nordisk faces intense competition from Eli Lilly's tirzepatide products (Mounjaro and Zepbound), which have demonstrated superior weight loss results in head-to-head trials. Lilly's dual GIP/GLP-1 receptor agonist has gained market share, and Lilly's stock surpassed Novo Nordisk's market capitalization in early 2025.

Pricing and Access Concerns: Novo Nordisk has faced criticism over the high cost of Ozempic and Wegovy, particularly in the United States where the drugs are priced significantly higher than in other markets. Patient advocacy groups and policymakers have called for greater affordability and access to these medications.

Stock Price Decline: Novo Nordisk's stock declined from over $600 billion market capitalization at its September 2024 peak to approximately $100 billion by mid-2025, driven by the CagriSema trial disappointment, competitive pressure from Eli Lilly, and the CEO departure. The decline represented one of the largest destructions of market value in pharmaceutical industry history.